Area of research
Molecular Biology · Oncology
Research interest
Research focused on Brentuximab vedotin and Refractory (planetary science), with related work in Dacarbazine, Bendamustine, Oncology. Notable publications include 'Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma', 'Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL', and 'Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study'.
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma
Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study